XuYan

Xuyan Biotechnology is a biopharmaceutical company based in Shanghai, China, specializing in the development of innovative small molecule therapeutics. The company primarily focuses on targeted protein degradation (TPD) technology, utilizing its proprietary platform to design proteolysis-targeting chimeras (PROTACs) for challenging oncological targets. Its lead research efforts are directed toward addressing drug resistance in cancers such as prostate cancer by targeting the androgen receptor. Xuyan Biotechnology aims to translate advanced chemical biology into clinical-stage assets to provide new treatment options for patients with refractory solid tumors.